81 FR 13798 - Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services To Enhance the Safety and Availability of Platelets for Transfusion; Draft Guidance for Industry; Availability
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration Federal Register Volume 81, Issue 50 (March 15, 2016)
Food and Drug Administration
Federal Register Volume 81, Issue 50 (March 15, 2016)
| Page Range | 13798-13801 | |
| FR Document | 2016-05718 |
[Federal Register Volume 81, Number 50 (Tuesday, March 15, 2016)] [Notices] [Pages 13798-13801] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2016-05718] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2014-D-1814] Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services To Enhance the Safety and Availability of Platelets for Transfusion; Draft Guidance for Industry; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice of availability. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft document entitled ``Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion; Draft Guidance for Industry.'' The draft guidance document provides blood collection establishments and transfusion services with recommendations to control the risk of bacterial contamination of room temperature stored platelets intended for transfusion through the implementation of pathogen reduction technology (PRT) or bacterial testing. The draft guidance also provides recommendations for the use of secondary testing of platelets as the basis to extend the dating period of platelets, when appropriately labeled bacterial detection devices and storage containers are used. The draft guidance replaces the draft guidance entitled ``Bacterial Detection Testing by Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion,'' dated December 2014. The draft guidance, when finalized, is intended to supersede the recommendation in section VII.A.2, in regard to bacterial contamination testing in the document entitled ``Guidance for Industry and FDA Review Staff: Collection of Platelets by Automated Methods'' dated December 2007. [[Page 13799]] DATES: Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance, submit either electronic or written comments on the draft guidance by June 13, 2016. Submit either electronic or written comments on the collection of information by May 16, 2016. ADDRESSES: You may submit comments as follows: Electronic Submissions Submit electronic comments in the following way:Federal eRulemaking Portal: http://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to http://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on http://www.regulations.gov. If you want to submit a comment with confidential information that you do not wish to be made available to the public submit the comment as a written/paper submission and in the manner detailed (see ``Written/Paper Submissions'' and ``Instructions''). Written/Paper Submissions Submit written/paper submissions as follows: Mail/Hand delivery/Courier (for written/paper submissions): Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. For written/paper comments submitted to the Division of Dockets Management, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ``Instructions.'' Instructions: All submissions received must include the Docket No. FDA-2014-D-1814 for ``Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion; Draft Guidance for Industry.'' Received comments will be placed in the docket and, except for those submitted as ``Confidential Submissions,'' publicly viewable at http://www.regulations.gov or at the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. Confidential Submissions--To submit a comment with confidential information that you do not wish to be made publicly available submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on http://www.regulations.gov. Submit both copies to the Division of Dockets Management. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ``confidential.'' Any information marked as ``confidential'' will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: http://www.fda.gov/regulatoryinformation/dockets/default.htm. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to http://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ``Search'' box and follow the prompts and/or go to the Division of Dockets Management, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Submit written requests for single copies of the draft guidance to the Office of Communication, Outreach and Development, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 3128, Silver Spring, MD 20993- 0002. Send one self-addressed adhesive label to assist the office in processing your requests. The draft guidance may also be obtained by mail by calling CBER at 1-800-835-4709 or 240-402-8010. See SUPPLEMENTARY INFORMATION section for electronic access to the draft guidance document. FOR FURTHER INFORMATION CONTACT: Information Collection Requirements: FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver Spring, MD 20993-0002, [email protected]. Guidance Document: Jonathan McKnight, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240- 402-7911. SUPPLEMENTARY INFORMATION: I. Background FDA is announcing the availability of a draft document entitled ``Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion; Draft Guidance for Industry.'' Platelets are associated with a higher risk of sepsis and are related to more fatalities than any other transfusable blood component. The risk of bacterial contamination of platelets is a leading risk of infection from blood transfusion. This risk has persisted despite numerous interventions including the introduction, in the last decade, of analytically sensitive culture-based bacterial detection methods, which are widely used to test platelets prior to their release from blood collection establishments to transfusion services. The draft guidance provides blood collection establishments and transfusion services with recommendations to control the risk of bacterial contamination of room temperature stored platelets intended for transfusion through the implementation of PRT or bacterial testing. PRT is performed shortly after platelet collection by blood collection establishments. Bacterial testing encompasses primary testing of platelets by blood collection establishments and subsequent secondary testing prior to transfusion primarily by transfusion services. The draft guidance also provides recommendations for the use of secondary testing of platelets as the basis to extend the dating period of platelets, when appropriately labeled bacterial detection devices and storage containers are used. Additionally, the draft guidance provides recommendations to licensed blood establishments for submitting biologics license application supplements to [[Page 13800]] include bacterial testing of platelet components. The guidance informs transfusion services that are currently exempt from registration and blood product listing that if they choose to perform secondary testing of platelets to extend the dating period, they must register with FDA and list the blood products they manufacture. The draft guidance applies to all platelet products, including platelets manufactured from Whole Blood (Whole Blood Derived (WBD) platelets), platelets collected by automated methods from a single donor (apheresis platelets), pooled platelets, and platelets stored in additive solutions. The draft guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the current thinking of FDA on bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative if it satisfies the requirements of the applicable statutes and regulations. II. Paperwork Reduction Act of 1995 Under the PRA (44 U.S.C. 3501-3520), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document. With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology. Title: Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion. Description: We have identified the following recommendations in the draft guidance document as collections of information. In section VI, the draft guidance recommends that blood collection establishments have in place measures to promptly alert the transfusion services in the event that a distributed platelet product is subsequently identified as positive for bacterial contamination. In section X.A.2, the draft guidance recommends that following secondary testing, labeling on the container label or a tie-tag, should relay the following information: (1) Type of bacterial detection test performed (rapid or culture) and (2) the date and time the bacterial detection test was performed. Description of Respondents: The third-party disclosure recommendations described in the draft guidance affect blood collection establishments and transfusion services that collect and manufacture platelet products for transfusion, including WBD platelets, apheresis platelets, pooled platelets, and platelets stored in additive solutions. Burden Estimate: The Agency believes the information collection provision for blood collection establishments in section VI does not create a new burden for respondents and is part of usual and customary business practice. Blood collection establishments currently have in place standard operating procedures for notifying consignees (transfusion services) if a distributed platelet product has subsequently tested positive for bacterial contamination. In section X.A.2, the draft guidance recommends that following secondary testing, establishments should maintain a labeling process that relays certain information and is integral to the container (e.g., on the container label or an attached tie-tag) and label accordingly. FDA estimates the burden of this collection of information as follows: Table 1--Estimated Annual Third-Party Disclosure Burden \1\ -------------------------------------------------------------------------------------------------------------------------------------------------------- Number of Activity Number of disclosures per Total annual Average burden per disclosure Total hours respondents respondent disclosures -------------------------------------------------------------------------------------------------------------------------------------------------------- Section X.A.2: Following secondary testing, 2480 403 1,000,000 .05 (3 minutes)................... 50,000 maintain a labeling process that relays certain information and is integral to the container (e.g., on the container label or an attached tie-tag) and label accordingly. -------------------------------------------------------------------------------------------------------------------------------------------------------- \1\ There are no capital costs or operating and maintenance costs associated with this collection of information. Table 1 provides an estimate of the annual third-party disclosure burden for the information to be submitted in accordance with the draft guidance. Based on FDA data and information submitted by industry, FDA believes that there are approximately 2 million platelet transfusions per year. The recommendation for labeling following secondary testing applies to approximately 4,960 transfusion services in the Unites States. We estimate that about 50 percent of all platelets will be pathogen-reduced and 50 percent will be cultured. Therefore, to estimate the annual third-party disclosure burden in table 1, we assume that approximately one-half of the transfusion services will label one- half of the total platelets intended for transfusion in the United States following secondary testing. The average burden disclosure for transfusion services to implement the recommendation in table 1 is based on FDA's experience and industry information. This draft guidance also refers to previously approved collections of information found in FDA regulations. The collections of information in 21 CFR 601.12 and 610.60 have been approved under OMB control number [[Page 13801]] 0910-0338; the collections of information in 21 CFR 606.65, 606.100, 606.120, 606.121, 606.122, and have been approved under OMB control number 0910-0116; and the collections of information in 21 CFR part 607 have been approved under OMB control number 0910-0052. To ensure that comments on information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB (see ADDRESSES). All comments should be identified with the title of the information collection. In compliance with the PRA (44 U.S.C. 3407(d)), the Agency has submitted the information collection provisions of this document to OMB for review. These requirements will not be effective until FDA obtains OMB approval. FDA will publish a notice concerning OMB approval of these requirements in the Federal Register. III. Electronic Access Persons with access to the Internet may obtain the draft guidance at either http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or http://www.regulations.gov. Dated: March 9, 2016. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2016-05718 Filed 3-14-16; 8:45 am] BILLING CODE 4164-01-P
![13798 Federal Register / Vol. 81, No. 50 / Tuesday, March 15, 2016 / Notices
Active Dosage Form/
Application No. Drug Name Strength(s) Applicant
Ingredient(s) Route
NDA 011602 ......... KENALOG ............ Triamcinolone 0.025%; 0.1% ..................................... Lotion; Topical ..... Delcor Asset Corp.
Acetonide.
NDA 016059 ......... INDOCIN .............. Indomethacin ....... 25 milligrams (mg); 50 mg ................. Capsule; Oral ....... Iroko Pharma-
ceuticals, LLC.
NDA 017560 ......... BACTRIM and Sulfamethoxazole; 200 mg/5 milliliters (mL); 40 mg/5 mL Suspension; Oral Mutual Pharma-
BACTRIM PEDI- Trimethoprim. ceutical Com-
ATRIC. pany, Inc.
NDA 017598 ......... SEPTRA and Sulfamethoxazole; 200 mg/5 mL; 40 mg/5 mL ................. Suspension; Oral Monarch Pharma-
SEPTRA Trimethoprim. ceuticals, Inc.
GRAPE.
NDA 018185 ......... INDOCIN SR ........ Indomethacin ....... 75 mg ................................................. Extended-Release Iroko Pharma-
Capsule; Oral. ceuticals, LLC.
NDA 018450 ......... NITROPRESS ...... Sodium 50 mg/vial ........................................... Injectable; Injec- AbbVie Inc.
Nitroprusside. tion.
NDA 019834 ......... PLENDIL .............. Felodipine ............ 2.5 mg; 5 mg; 10 mg .......................... Extended-Release AstraZeneca.
Tablet; Oral.
NDA 021475 ......... METHYLIN ........... Methylphenidate 2.5 mg; 5 mg; 10 mg .......................... Chewable Tablet; Mallinckrodt Phar-
Hydrochloride. Oral. maceuticals.
NDA 050320 ......... UNIPEN ................ Nafcillin Sodium ... Equal to (EQ) 500 mg base/vial; EQ Injectable; Injec- Wyeth Ayerst
1 g (gram) base/vial; EQ 2 g base/ tion. Pharma-
vial; EQ 4 g base/vial; EQ 10 g ceuticals.
base/vial; EQ 20 g base/vial.
NDA 050406 ......... KEFLEX ............... Cephalexin ........... EQ 125 mg base/5 mL; EQ 250 mg For Suspension; Shionogi Inc.
base/5 mL; EQ 100 mg base/mL. Oral.
ANDA 060576 ...... MYCOLOG–II ....... Nystatin; 100,000 units/g; 0.1% ........................ Cream; Topical ..... Delcor Asset Corp.
Triamcinolone
Acetonide.
ANDA 062117 ...... CEPHALEXIN ...... Cephalexin ........... EQ 125 mg base/5 mL; EQ 250 mg For suspension; Facta Farmaceutici
base/5 mL; EQ 100 mg base/mL. Oral. S.p.A.
ANDA 062606 ...... MYCOLOG–II ....... Nystatin; 100,000 units/g; 0.1% ........................ Cream; Topical ..... Delcor Asset Corp.
Triamcinolone
Acetonide.
ANDA 062717 ...... UNIPEN ............... Nafcillin Sodium ... EQ 500 mg base/vial; EQ 1 g base/ Injectable; Injec- Wyeth Ayerst
vial; EQ 2 g base/vial. tion. Pharma-
ceuticals.
FDA has reviewed its records and, Dated: March 9, 2016. Draft Guidance for Industry.’’ The draft
under § 314.161, has determined that Leslie Kux, guidance document provides blood
the drug products listed in this Associate Commissioner for Policy. collection establishments and
document were not withdrawn from [FR Doc. 2016–05717 Filed 3–14–16; 8:45 am] transfusion services with
sale for reasons of safety or BILLING CODE 4164–01–P recommendations to control the risk of
effectiveness. Accordingly, the Agency bacterial contamination of room
will continue to list the drug products temperature stored platelets intended
listed in this document in the DEPARTMENT OF HEALTH AND for transfusion through the
‘‘Discontinued Drug Product List’’ HUMAN SERVICES implementation of pathogen reduction
section of the Orange Book. The technology (PRT) or bacterial testing.
Food and Drug Administration The draft guidance also provides
‘‘Discontinued Drug Product List’’
identifies, among other items, drug [Docket No. FDA–2014–D–1814] recommendations for the use of
products that have been discontinued secondary testing of platelets as the
from marketing for reasons other than Bacterial Risk Control Strategies for basis to extend the dating period of
safety or effectiveness. Blood Collection Establishments and platelets, when appropriately labeled
Transfusion Services To Enhance the bacterial detection devices and storage
Approved ANDAs that refer to the Safety and Availability of Platelets for containers are used. The draft guidance
NDAs and ANDAs listed in this Transfusion; Draft Guidance for replaces the draft guidance entitled
document are unaffected by the Industry; Availability ‘‘Bacterial Detection Testing by Blood
discontinued marketing of the products Collection Establishments and
subject to those NDAs and ANDAs. AGENCY: Food and Drug Administration,
HHS. Transfusion Services to Enhance the
Additional ANDAs that refer to these Safety and Availability of Platelets for
products may also be approved by the ACTION: Notice of availability.
Transfusion,’’ dated December 2014.
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Agency if they comply with relevant SUMMARY: The Food and Drug The draft guidance, when finalized, is
legal and regulatory requirements. If Administration (FDA or Agency) is intended to supersede the
FDA determines that labeling for these announcing the availability of a draft recommendation in section VII.A.2, in
drug products should be revised to meet document entitled ‘‘Bacterial Risk regard to bacterial contamination testing
current standards, the Agency will Control Strategies for Blood Collection in the document entitled ‘‘Guidance for
advise ANDA applicants to submit such Establishments and Transfusion Industry and FDA Review Staff:
labeling. Services to Enhance the Safety and Collection of Platelets by Automated
Availability of Platelets for Transfusion; Methods’’ dated December 2007.
VerDate Sep<11>2014 17:40 Mar 14, 2016 Jkt 238001 PO 00000 Frm 00028 Fmt 4703 Sfmt 4703 E:\FR\FM\15MRN1.SGM 15MRN1](https://thefederalregister.org/doc/81_FR_13848/page/1.svg)
![Federal Register / Vol. 81, No. 50 / Tuesday, March 15, 2016 / Notices 13801
0910–0338; the collections of SUMMARY: The Food and Drug device is in short supply or is needed
information in 21 CFR 606.65, 606.100, Administration (FDA) is announcing for national emergency, (3) facilitation
606.120, 606.121, 606.122, and have that a proposed collection of of recalls for devices marketed by
been approved under OMB control information has been submitted to the owners and operators of device
number 0910–0116; and the collections Office of Management and Budget establishments, (4) identification and
of information in 21 CFR part 607 have (OMB) for review and clearance under cataloguing of marketed devices, (5)
been approved under OMB control the Paperwork Reduction Act of 1995. administering postmarketing
number 0910–0052. DATES: Fax written comments on the surveillance programs for devices, (6)
To ensure that comments on collection of information by April 14, identification of devices marketed in
information collection are received, 2016. violation of the law, (7) identification
OMB recommends that written and control of devices imported into the
ADDRESSES: To ensure that comments on
comments be faxed to the Office of country from foreign establishments, (8)
the information collection are received,
Information and Regulatory Affairs, and scheduling and planning
OMB recommends that written
OMB (see ADDRESSES). All comments inspections of registered establishments
comments be faxed to the Office of
should be identified with the title of the under section 704 of the FD&C Act (21
Information and Regulatory Affairs,
information collection. U.S.C. 374).
OMB, Attn: FDA Desk Officer, FAX:
In compliance with the PRA (44 Respondents to this information
202–395–7285, or emailed to oira_
U.S.C. 3407(d)), the Agency has collection are owners or operators of
submission@omb.eop.gov. All
submitted the information collection establishments that engage in the
comments should be identified with the
provisions of this document to OMB for manufacturing, preparation,
OMB control number 0910–0625. Also
review. These requirements will not be propagation, compounding, or
include the FDA docket number found
effective until FDA obtains OMB processing of a device or devices, who
in brackets in the heading of this
approval. FDA will publish a notice must register their establishments and
document.
concerning OMB approval of these submit listing information for each of
requirements in the Federal Register. FOR FURTHER INFORMATION CONTACT: FDA their devices in commercial
PRA Staff, Office of Operations, Food distribution. Notwithstanding certain
III. Electronic Access and Drug Administration, 8455 exceptions, foreign device
Persons with access to the Internet Colesville Rd., COLE–14526, Silver establishments that manufacture,
may obtain the draft guidance at either Spring, MD 20993–0002, PRAStaff@ prepare, propagate, compound, or
http://www.fda.gov/BiologicsBlood fda.hhs.gov. process a device that is imported or
Vaccines/GuidanceCompliance SUPPLEMENTARY INFORMATION: In offered for import into the United States
RegulatoryInformation/Guidances/ compliance with 44 U.S.C. 3507, FDA must also comply with the registration
default.htm or http:// has submitted the following proposed and listing requirements. The number of
www.regulations.gov. collection of information to OMB for respondents is based on data from the
Dated: March 9, 2016. review and clearance. FDA Unified Registration and Listing
Leslie Kux, System.
Electronic Submission of Medical Burden estimates are based on recent
Associate Commissioner for Policy. Device Registration and Listing—21 experience with the existing medical
[FR Doc. 2016–05718 Filed 3–14–16; 8:45 am] CFR Part 807, Subparts A Through D; device registration and listing program,
BILLING CODE 4164–01–P OMB Control Number 0910–0625— electronic system operating experience,
Extension and the economic analysis for the final
DEPARTMENT OF HEALTH AND Under section 510 of the Federal rule entitled ‘‘Implementation of Device
HUMAN SERVICES Food, Drug, and Cosmetic Act (the Registration and Listing Requirements
FD&C Act) (21 U.S.C. 360) and part 807, Enacted in the Public Health Security
Food and Drug Administration subparts A through D (21 CFR part 807, and Bioterrorism Preparedness and
subparts A through D), medical device Response Act of 2002, the Medical
[Docket No. FDA–2015–N–3815] establishment owners and operators are Device User Fee and Modernization Act
required to electronically submit of 2002, and Title II of the Food and
Agency Information Collection establishment registration and device Drug Administration Amendments Act
Activities; Submission for Office of listing information. of 2007.’’
Management and Budget Review; Complete and accurate registration In the Federal Register of October 27,
Comment Request; Electronic and listing information is necessary to 2015 (80 FR 65779), FDA published a
Submission of Medical Device accomplish a number of statutory and 60-day notice requesting public
Registration and Listing regulatory objectives, such as: (1) comment on the proposed collection of
AGENCY: Food and Drug Administration, Identification of establishments information. No comments were
HHS. producing marketed medical devices, received.
(2) identification of establishments FDA estimates the burden of this
ACTION: Notice.
producing a specific device when that collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Number of Average
Number of Total annual
21 CFR Section FDA Form No. responses per burden per Total hours
respondents responses
respondent response
807.20(a)(5) 2—Submittal of manufac- 3673 8,594 1 8,594 1.75 ................ 15,040
turer information by initial importers.
807.20(a)(5) 3—Submittal of manufac- 3673 8,594 3 25,782 .1 .................... 2,578
turer information by initial importers. (6 minutes) .....
VerDate Sep<11>2014 17:40 Mar 14, 2016 Jkt 238001 PO 00000 Frm 00031 Fmt 4703 Sfmt 4703 E:\FR\FM\15MRN1.SGM 15MRN1](https://thefederalregister.org/doc/81_FR_13848/page/4.svg)
Document Created: 2016-03-15 04:07:35
Document Modified: 2016-03-15 04:07:35
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice of availability. | |
| Dates | Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance, submit either electronic or written comments on the draft guidance by June 13, 2016. Submit either electronic or written comments on the collection of information by May 16, 2016. | |
| Contact | Information Collection Requirements: FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver Spring, MD 20993-0002, [email protected] | |
| FR Citation | 81 FR 13798 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR